Loss of chromosome 18q11.2-18q12.1 is predictive for progression-free survival in metastatic colorectal cancer patients treated with bevacizumab

Author(s):
Dijk, E. van; Biesma, H.; Cordes, M.; Smeets, D.; Neerincx, M.; ; Murphy, V.; Barat, A.; Bacon, O.; Prehn, J.H.M.; Betge, J.; Timo, G.; Fender, B.; Meijer, G.A.; McNamara, D.A.; Klinger, R.; Koopman, M.; Ebert, M.P.A.; Kay, E.W.; Hennessey, B.T.; Verheul, H.M.W.; Gallagher, W.M.; O'Connor, D.P.; Punt, C.J.A.; Loupakis, F.; Lambrechts, D.; Byrne, A.; Grieken, N.C.T. van; Ylstra, B.
Published
2018
Publication type
Article / Letter to editor
Date issued
2018-07-31
Language
English
Is part of
Cancer Research (2018), No. 13
hdl
1887/96465
doi
10.1158/1538-7445.AM2018-2579